Evaluation of Risk Factors for Hepatic Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Background:  Hepatic dysfunction in patients who have undergone allogeneic haematopoietic stem cell transplantation (HSCT) is a major cause of morbidity and mortality. The aim of this study is to evaluate the incidence of post-transplantation hepatic complications in these patients. Methods: A tot...

Full description

Bibliographic Details
Main Authors: Zahrasadat Mirmoezi, Molouk Hadjibabaie, Ava Mansouri, Hamidreza Taghvaye Masoumi, Zahra Jahangard-Rafsanjani, Hossein Kamranzadeh
Format: Article
Language:English
Published: Research Center for Rational Use of Drugs (RCRUD) 2017-09-01
Series:Journal of Pharmaceutical Care
Subjects:
Online Access:https://jpc.tums.ac.ir/index.php/jpc/article/view/142
id doaj-e3866b0256ff44c8a3673398a644ac43
record_format Article
spelling doaj-e3866b0256ff44c8a3673398a644ac432020-11-25T03:42:59ZengResearch Center for Rational Use of Drugs (RCRUD)Journal of Pharmaceutical Care2322-46302322-45092017-09-0141-291Evaluation of Risk Factors for Hepatic Complications after Allogeneic Hematopoietic Stem Cell TransplantationZahrasadat Mirmoezi0Molouk Hadjibabaie1Ava Mansouri2Hamidreza Taghvaye Masoumi3Zahra Jahangard-Rafsanjani4Hossein Kamranzadeh5Faculty of Pharmacy,Tehran University of Medical Sciences, Tehran, IranClinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranResearch Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, IranClinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranClinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranHematologyOncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Background:  Hepatic dysfunction in patients who have undergone allogeneic haematopoietic stem cell transplantation (HSCT) is a major cause of morbidity and mortality. The aim of this study is to evaluate the incidence of post-transplantation hepatic complications in these patients. Methods: A total of 121 patients (age above 15 with no abnormality in their hepatic tests) participated in the study. The influence of a variety of risk factors on the incidence, type, and pattern of hepatic dysfunction as well as the length of hospital stay related to these complications were studied. Results:  As a whole, 76 patients (62%)—44 males and 32 females—were diagnosed with hepatic dysfunction after transplantation. As many as 31(25%) of the patients showed increased measures in their hepatic enzyme, while 45(37%) of them ended up with both abnormal enzyme measure and clinical symptoms including diarrhoea, skin rash, jaundice, and anorexia. The hepatic dysfunction rates owing to drug toxicity and GVHD (21.5% and 16.5%, respectively) proved to be the highest in our study. Analysing risk factors, the immunosuppressive regimen could affect the type of hepatic dysfunction—i.e., less patients with GVHD were found in the group who received ATG in their regimen (p-value =0.034). Conclusion: According to these findings, the immunosuppressive regimen can play a role in preventing the incidence of GVHD. Less occurrence of hepatic complications, especially GVHD, may lead to less clinical symptoms and time of hospital stay. https://jpc.tums.ac.ir/index.php/jpc/article/view/142hepatotoxicityHSCTrisk factors
collection DOAJ
language English
format Article
sources DOAJ
author Zahrasadat Mirmoezi
Molouk Hadjibabaie
Ava Mansouri
Hamidreza Taghvaye Masoumi
Zahra Jahangard-Rafsanjani
Hossein Kamranzadeh
spellingShingle Zahrasadat Mirmoezi
Molouk Hadjibabaie
Ava Mansouri
Hamidreza Taghvaye Masoumi
Zahra Jahangard-Rafsanjani
Hossein Kamranzadeh
Evaluation of Risk Factors for Hepatic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
Journal of Pharmaceutical Care
hepatotoxicity
HSCT
risk factors
author_facet Zahrasadat Mirmoezi
Molouk Hadjibabaie
Ava Mansouri
Hamidreza Taghvaye Masoumi
Zahra Jahangard-Rafsanjani
Hossein Kamranzadeh
author_sort Zahrasadat Mirmoezi
title Evaluation of Risk Factors for Hepatic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
title_short Evaluation of Risk Factors for Hepatic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
title_full Evaluation of Risk Factors for Hepatic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
title_fullStr Evaluation of Risk Factors for Hepatic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
title_full_unstemmed Evaluation of Risk Factors for Hepatic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
title_sort evaluation of risk factors for hepatic complications after allogeneic hematopoietic stem cell transplantation
publisher Research Center for Rational Use of Drugs (RCRUD)
series Journal of Pharmaceutical Care
issn 2322-4630
2322-4509
publishDate 2017-09-01
description Background:  Hepatic dysfunction in patients who have undergone allogeneic haematopoietic stem cell transplantation (HSCT) is a major cause of morbidity and mortality. The aim of this study is to evaluate the incidence of post-transplantation hepatic complications in these patients. Methods: A total of 121 patients (age above 15 with no abnormality in their hepatic tests) participated in the study. The influence of a variety of risk factors on the incidence, type, and pattern of hepatic dysfunction as well as the length of hospital stay related to these complications were studied. Results:  As a whole, 76 patients (62%)—44 males and 32 females—were diagnosed with hepatic dysfunction after transplantation. As many as 31(25%) of the patients showed increased measures in their hepatic enzyme, while 45(37%) of them ended up with both abnormal enzyme measure and clinical symptoms including diarrhoea, skin rash, jaundice, and anorexia. The hepatic dysfunction rates owing to drug toxicity and GVHD (21.5% and 16.5%, respectively) proved to be the highest in our study. Analysing risk factors, the immunosuppressive regimen could affect the type of hepatic dysfunction—i.e., less patients with GVHD were found in the group who received ATG in their regimen (p-value =0.034). Conclusion: According to these findings, the immunosuppressive regimen can play a role in preventing the incidence of GVHD. Less occurrence of hepatic complications, especially GVHD, may lead to less clinical symptoms and time of hospital stay.
topic hepatotoxicity
HSCT
risk factors
url https://jpc.tums.ac.ir/index.php/jpc/article/view/142
work_keys_str_mv AT zahrasadatmirmoezi evaluationofriskfactorsforhepaticcomplicationsafterallogeneichematopoieticstemcelltransplantation
AT moloukhadjibabaie evaluationofriskfactorsforhepaticcomplicationsafterallogeneichematopoieticstemcelltransplantation
AT avamansouri evaluationofriskfactorsforhepaticcomplicationsafterallogeneichematopoieticstemcelltransplantation
AT hamidrezataghvayemasoumi evaluationofriskfactorsforhepaticcomplicationsafterallogeneichematopoieticstemcelltransplantation
AT zahrajahangardrafsanjani evaluationofriskfactorsforhepaticcomplicationsafterallogeneichematopoieticstemcelltransplantation
AT hosseinkamranzadeh evaluationofriskfactorsforhepaticcomplicationsafterallogeneichematopoieticstemcelltransplantation
_version_ 1724522103720378368